Search

Your search keyword '"Gardini, Andrea Casadei"' showing total 8 results
Start Over Author "Gardini, Andrea Casadei" Journal oncotarget
8 results on '"Gardini, Andrea Casadei"'

1. Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review

Author

Gardini, Andrea Casadei, primary, Santini, Daniele, additional, Aprile, Giuseppe, additional, Silvestris, Nicola, additional, Felli, Emanuele, additional, Foschi, Francesco Giuseppe, additional, Ercolani, Giorgio, additional, Marisi, Giorgia, additional, Valgiusti, Martina, additional, Passardi, Alessandro, additional, Puzzoni, Marco, additional, Silletta, Marianna, additional, Brunetti, Oronzo, additional, Cardellino, Giovanni Gerardo, additional, Frassineti, Giovanni Luca, additional, and Scartozzi, Mario, additional

Published
2017
Full Text
View/download PDF

2. Immunotherapeutic approaches for hepatocellular carcinoma

Author

Longo, Vito, primary, Gnoni, Antonio, additional, Gardini, Andrea Casadei, additional, Pisconti, Salvatore, additional, Licchetta, Antonella, additional, Scartozzi, Mario, additional, Memeo, Riccardo, additional, Palmieri, Vincenzo Ostilio, additional, Aprile, Giuseppe, additional, Santini, Daniele, additional, Nardulli, Patrizia, additional, Silvestris, Nicola, additional, and Brunetti, Oronzo, additional

Published
2017
Full Text
View/download PDF

3. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

Author

Gardini, Andrea Casadei, primary, Scarpi, Emanuela, additional, Faloppi, Luca, additional, Scartozzi, Mario, additional, Silvestris, Nicola, additional, Santini, Daniele, additional, de Stefano, Giorgio, additional, Marisi, Giorgia, additional, Negri, Francesca V., additional, Foschi, Francesco Giuseppe, additional, Valgiusti, Martina, additional, Ercolani, Giorgio, additional, and Frassineti, Giovanni Luca, additional

Published
2016
Full Text
View/download PDF

4. Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions

Author

Gardini, Andrea Casadei, primary, Tenti, Elena, additional, Masini, Carla, additional, Nanni, Oriana, additional, Scarpi, Emanuela, additional, Valgiusti, Martina, additional, Restuccia, Silvia, additional, Gallani, Maria Laura, additional, Palazzini, Simonetta, additional, Bianchini, Erica, additional, Menozzi, Silvia, additional, Maugeri, Antonio, additional, Amadori, Dino, additional, Minguzzi, Martina, additional, and Frassineti, Giovanni Luca, additional

Published
2016
Full Text
View/download PDF

5. eNOSpolymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study

Author

Gardini, Andrea Casadei, primary, Marisi, Giorgia, additional, Faloppi, Luca, additional, Scarpi, Emanuela, additional, Foschi, Francesco Giuseppe, additional, Iavarone, Massimo, additional, Lauletta, Gianfranco, additional, Corbelli, Jody, additional, Valgiusti, Martina, additional, Facchetti, Floriana, additional, Corte, Cristina della, additional, Neri, Luca Maria, additional, Tamberi, Stefano, additional, Cascinu, Stefano, additional, Scartozzi, Mario, additional, Amadori, Dino, additional, Nanni, Oriana, additional, Tenti, Elena, additional, Ulivi, Paola, additional, and Frassineti, Giovanni Luca, additional

Published
2016
Full Text
View/download PDF

6. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group

Author

Gardini, Andrea Casadei, primary, Scarpi, Emanuela, additional, Marisi, Giorgia, additional, Foschi, Francesco Giuseppe, additional, Donati, Gabriele, additional, Giampalma, Emanuela, additional, Faloppi, Luca, additional, Scartozzi, Mario, additional, Silvestris, Nicola, additional, Bisulli, Marcello, additional, Corbelli, Jody, additional, Gardini, Andrea, additional, Barba, Giuliano La, additional, Veneroni, Luigi, additional, Tamberi, Stefano, additional, Cascinu, Stefano, additional, and Frassineti, Giovanni Luca, additional

Published
2016
Full Text
View/download PDF

7. Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial

Author

Gardini, Andrea Casadei, primary, Carloni, Silvia, additional, Scarpi, Emanuela, additional, Maltoni, Paolo, additional, Dorizzi, Romolo M., additional, Passardi, Alessandro, additional, Frassineti, Giovanni Luca, additional, Cortesi, Pietro, additional, Giannini, Maria Benedetta, additional, Marisi, Giorgia, additional, Amadori, Dino, additional, and Lucchesi, Alessandro, additional

Published
2016
Full Text
View/download PDF

8. Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions

Author

Silvia Menozzi, Dino Amadori, Giovanni Luca Frassineti, Erica Bianchini, Elena Tenti, Oriana Nanni, Martina Valgiusti, Silvia Restuccia, Antonio Maugeri, Simonetta Palazzini, Andrea Casadei Gardini, Carla Masini, Martina Minguzzi, Emanuela Scarpi, Maria Laura Gallani, Gardini, Andrea Casadei, Tenti, Elena, Masini, Carla, Nanni, Oriana, Scarpi, Emanuela, Valgiusti, Martina, Restuccia, Silvia, Gallani, Maria Laura, Palazzini, Simonetta, Bianchini, Erica, Menozzi, Silvia, Maugeri, Antonio, Amadori, Dino, Minguzzi, Martina, and Frassineti, Giovanni Luca

Subjects
0301 basic medicine, Niacinamide, medicine.medical_specialty, Organoplatinum Compounds, Antineoplastic Agents, Docetaxel, Capecitabine, Oxaliplatin, Pathology section, Pharmacovigilance, Sorafenib, Oncology, Drug Administration Schedule, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Neoplasms, Medicine, Humans, Medical prescription, Adverse effect, Retrospective Studies, business.industry, Phenylurea Compounds, capecitabine, oxaliplatin, Retrospective cohort study, Carboplatin, Surgery, 030104 developmental biology, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Taxoids, Clinical Research Paper, business, medicine.drug
Abstract

Antiblastic drugs have a high number of potential side-effects. Paradoxically, according to the National Network of Pharmacovigilance, the number of reported adverse reactions to these agents is proportionally lower than that registered for non antiblastic drugs. Critical phenomena such as treatment interruptions and significant dose reductions within the first two months of use may be indicators of adverse drug reactions. The aim of the present study was to increase our knowledge of pharmacovigilance to facilitate the actions taken to improve the risk-benefit profile of cancer drugs and, consequently, their safety. This retrospective observational survey was carried out on prescriptions from 1st January 2012 to 31st December 2012. Dose reductions of more than 10% during the first 90 days of therapy were considered as a surrogate indicator of an adverse reaction. Dose interruptions during the first 60 days of therapy were taken into consideration. Of the12,472 patients 1,248 underwent a dose reduction. The drugs that most often required a dose reduction were paclitaxel and oxaliplatin (17.4% and 17.3%, respectively), docetaxel (14.8%), carboplatin (15%), fluorouracil (10.7%) and, among oral medications, capecitabine (6.9%). Of the 1896 patients treated with the same drugs, 9.7% interrupted treatment. Patients required a lower dose reduction than that reported by other authors. Around 15% of cases underwent a 30% dose reduction within three months of starting therapy, indicating a possible adverse reaction. Constant monitoring of dose prescription and continuous training of medical and nursing staff are clearly needed to increase awareness of the importance of reporting adverse events.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results